Paratek Pharmaceuticals Inc (PRTK) Receives $42.71 Consensus Target Price from Analysts
Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) have earned an average recommendation of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $40.00.
Several brokerages have commented on PRTK. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a research note on Wednesday. Cantor Fitzgerald restated a “buy” rating and issued a $50.00 target price on shares of Paratek Pharmaceuticals in a research report on Thursday, September 21st. ValuEngine cut Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, December 29th. Robert W. Baird restated a “buy” rating and issued a $40.00 target price on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. Finally, Guggenheim assumed coverage on Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They issued a “buy” rating and a $44.00 target price on the stock.
Shares of Paratek Pharmaceuticals (NASDAQ:PRTK) traded up $0.05 during trading hours on Monday, reaching $18.20. The company’s stock had a trading volume of 267,245 shares, compared to its average volume of 372,681. The firm has a market capitalization of $508.53, a price-to-earnings ratio of -4.88 and a beta of 0.70. The company has a debt-to-equity ratio of 0.49, a current ratio of 10.53 and a quick ratio of 10.53. Paratek Pharmaceuticals has a 12 month low of $13.95 and a 12 month high of $29.00.
ILLEGAL ACTIVITY NOTICE: “Paratek Pharmaceuticals Inc (PRTK) Receives $42.71 Consensus Target Price from Analysts” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/12/paratek-pharmaceuticals-inc-prtk-receives-42-71-consensus-target-price-from-analysts.html.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Stock Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related stocks with our FREE daily email newsletter.